Literature DB >> 31630251

Trends in incidence of small bowel cancer according to histology: a population-based study.

Anne-Marie Bouvier1,2,3,4,5, Michel Robaszkiewicz6,7,8, Valérie Jooste9,10,11,6,12, Mélanie Cariou6,7, Antoine Drouillard9,10,11,12, Véronique Bouvier6,13, Jean-Baptiste Nousbaum6,7,8.   

Abstract

BACKGROUND: Small bowel cancer is not a single entity. Population-based studies taking into account histological diversity are scarce. The aim of this study was to report on their trends in incidence by histology in France over the past 20 years.
METHODS: All patients with a small bowel cancer diagnosed in 15 French administrative areas covered by a registry from the network of French cancer registries (FRANCIM) were included. Age-standardized incidence rates were estimated using the world standard population. Incidence rates were calculated by gender, age group, histology, and 5-year period.
RESULTS: The overall age-standardized incidence rates were 1.46/100,000 inhabitants in men and 0.9/100,000 inhabitants in women. Adenocarcinoma was the most common histological type (38%), followed by neuroendocrine tumors (35%), lymphoma (15%) and sarcoma (12%). Age at diagnosis and tumor location differed between adenocarcinoma and neuroendocrine tumors. The incidence of all four tumor types increased significantly over the 20-year period, with the exception of lymphoma in men. The annual percentage change for neuroendocrine tumors was 3.89% in men and 3.61% in women; for sarcoma, it was 3.38% and 4.08%, respectively. The incidence of adenocarcinoma and lymphoma also increased in women with an annual percentage change of 3.05% and 3.32%, respectively.
CONCLUSION: Small bowel cancer incidence has increased over time. This increase occurred with different amplitudes and patterns in the four major histological types. The improvement in imaging techniques could partly explain this increase. It is necessary to determine whether predisposing conditions may contribute to this change.

Entities:  

Keywords:  Cancer registry; Histology; Incidence; Small bowel cancer; Trends

Mesh:

Year:  2019        PMID: 31630251     DOI: 10.1007/s00535-019-01636-z

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo.

Authors:  Vanessa Palascak-Juif; Anne Marie Bouvier; Jacques Cosnes; Bernard Flourié; Olivier Bouché; Guillaume Cadiot; Marc Lémann; Bruno Bonaz; Christine Denet; Philippe Marteau; Luc Gambiez; Laurent Beaugerie; Jean Faivre; Franck Carbonnel
Journal:  Inflamm Bowel Dis       Date:  2005-09       Impact factor: 5.325

2.  Cancer risk in patients with inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; E Kliewer; A Wajda
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

3.  Incidence and management of primary malignant small bowel cancers: a well-defined French population study.

Authors:  Côme Lepage; Anne-Marie Bouvier; Sylvain Manfredi; Vincent Dancourt; Jean Faivre
Journal:  Am J Gastroenterol       Date:  2006-10-06       Impact factor: 10.864

4.  Risk factors for adenocarcinoma of the small intestine.

Authors:  E Negri; C Bosetti; C La Vecchia; F Fioretti; E Conti; S Franceschi
Journal:  Int J Cancer       Date:  1999-07-19       Impact factor: 7.396

5.  Primary small-bowel malignancy in the UK and its association with coeliac disease.

Authors:  P D Howdle; P K Jalal; G K T Holmes; R S Houlston
Journal:  QJM       Date:  2003-05

6.  Risk factors for small intestine cancer.

Authors:  W H Chow; M S Linet; J K McLaughlin; A W Hsing; H T Chien; W J Blot
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

7.  Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.

Authors:  Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

Review 8.  The epidemiology and pathogenesis of neoplasia in the small intestine.

Authors:  David Schottenfeld; Jennifer L Beebe-Dimmer; Fawn D Vigneau
Journal:  Ann Epidemiol       Date:  2009-01       Impact factor: 3.797

Review 9.  Histogenesis and natural history of gut neuroendocrine tumors: present status.

Authors:  Enrico Solcia; Alessandro Vanoli
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

10.  Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study.

Authors:  Georgia Malamut; Olivia Chandesris; Virginie Verkarre; Bertrand Meresse; Céline Callens; Elizabeth Macintyre; Yoram Bouhnik; Jean-Marc Gornet; Matthieu Allez; Raymond Jian; Anne Berger; Gilles Châtellier; Nicole Brousse; Olivier Hermine; Nadine Cerf-Bensussan; Christophe Cellier
Journal:  Dig Liver Dis       Date:  2013-01-10       Impact factor: 4.088

View more
  4 in total

1.  Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study.

Authors:  Giovanni Arpa; Matteo Fassan; Camilla Guerini; Erica Quaquarini; Federica Grillo; Valentina Angerilli; Vincenza Guzzardo; Sara Lonardi; Francesca Bergamo; Marco Vincenzo Lenti; Paolo Pedrazzoli; Marco Paulli; Antonio Di Sabatino; Alessandro Vanoli
Journal:  Virchows Arch       Date:  2022-08-04       Impact factor: 4.535

Review 2.  Epidemiology, Risk Factors and Diagnosis of Small Bowel Adenocarcinoma.

Authors:  Thomas Aparicio; Atanas Pachev; Pierre Laurent-Puig; Magali Svrcek
Journal:  Cancers (Basel)       Date:  2022-05-02       Impact factor: 6.575

3.  Genetic analysis of Japanese patients with small bowel adenocarcinoma using next-generation sequencing.

Authors:  Atsushi Tatsuguchi; Takeshi Yamada; Koji Ueda; Hiroyasu Furuki; Aitoshi Hoshimoto; Takayoshi Nishimoto; Jun Omori; Naohiko Akimoto; Katya Gudis; Shu Tanaka; Shunji Fujimori; Akira Shimizu; Katsuhiko Iwakiri
Journal:  BMC Cancer       Date:  2022-07-02       Impact factor: 4.638

4.  Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: A population-based analysis using Surveillance, Epidemiology, and End Result Program database.

Authors:  Tongtong Liu; Yunlong Wu; Tao Jiang
Journal:  Cancer Med       Date:  2020-08-04       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.